Discussion
SECONDARY
Our primary aim was to test whether a C-OLP intervention could improve methadone treatment outcomes. Our hypothesis that 90-day methadone doses would be lower for C-OLP than for TAU recipients was not supported. We can only speculate as to why there were no significant differences between the groups, but due to its bioavailability, clearance, and half-life, methadone dosing is highly individualized.Unexpectedly, we found a significant difference in the groups’ 90-day retention rates, with 61.1% retention attrition in the TAU group and 77.9% for group C-OLP (Additionally, secondary analyses suggested another benefit in the C-OLP group: relative to the TAU participants, they reported better sleep over the first 90 days of treatment, with an estimated mean PSQI score difference of 1.78 points (